Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug curb obesity in kids with movement challenges?

NCT ID NCT00720161

Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether metformin, a drug that improves insulin sensitivity, can help overweight children with neurological or neuromuscular conditions. These children often face mobility challenges that lead to a sedentary lifestyle and weight gain. The study compares six months of metformin against a placebo to see if it improves insulin resistance and blood fat levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, metformin could help manage weight and metabolic health in children with motor impairments, potentially improving their overall fitness and reducing obesity-related risks.
What could go wrong
This is a small trial, and metformin may not significantly improve insulin resistance or fat levels in this population. Possible side effects include gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Start date

Nov 2006

Finished

Jul 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with neurogenic or myogenic motor deficit, clinically obese or who had excessively gained weight over the last year. Exclusion Criteria: * Exclusion criteria were known type 1 or type 2 diabetes mellitus and contraindications to metformin therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuromuscular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy Insulin Resistance neuromuscular disease spina bifida

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuromuscular diseases Spina bifida

Contacts and locations

Locations

  • UZLeuven

    Leuven, Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.